Acromegaly Update

Acromegaly Update

By Ethan WeissScienceLife Sciences
Download on the App Store

Acromegaly Update episodes

  • Acromegaly Update — Monday November 16, 2026
    Another incremental week for acromegaly research, led by evidence that upper-limb joint damage is nearly universal in patients and an early AI voice test for diagnosis, while rare disease industry news was dominated by deal-making (Lilly's up-to-$1.5B Calytrix buyout, argenx's Unnatural Products acquisition), a positive pivotal hepatitis delta readout from Vir, and Novo's sickle cell filing.
    7 min
  • Acromegaly Update — Monday November 9, 2026
    A quiet week for top-tier acromegaly papers, with a useful surgical-outcome predictor and a new treatment-landscape review, while rare disease industry news was dominated by setbacks: a failed Becker muscular dystrophy trial, deep Ultragenyx layoffs, and a new safety signal for Zolgensma.
    5 min
  • Acromegaly Update — Monday November 2, 2026
    A quiet week for acromegaly, with no top-tier-journal papers and only incremental observational work (tumor size drives headache; surgical remission isn't predicted by tumor subtype), while rare disease industry news was dominated by an FDA draft framework for "plug and play" gene therapies and a fresh $90M launch in Charcot-Marie-Tooth.
    4 min
  • Acromegaly Update — Monday October 26, 2026
    A thin top-tier week for acromegaly (one Pituitary paper plus a handful of solid next-tier studies, including a 2026 pipeline review), while rare disease news was dominated by positive Phase 3 readouts from Disc Medicine and Roivant, a second FDA look at Biohaven's ataxia drug, and early Huntington's data from Alnylam.
    5 min
  • Acromegaly Update — Monday October 5, 2026
    A thin week: no top-tier-journal acromegaly papers appeared, so Part A draws on the next tier (a radiomics model to predict somatostatin-analog response, a familial Carney-complex case, and bone proteomics), while the rare disease industry's big story is uniQure's four-year Huntington's gene therapy data, which showed a smaller, non-significant benefit and sent the stock down about 40%.
    7 min
  • Acromegaly Update — Monday September 28, 2026
    A quiet week for top-tier acromegaly literature (four papers, mostly real-world/consensus rather than trial data) paired with a livelier rare disease industry week — a first-ever positive pivotal trial in X-linked retinitis pigmentosa and a new FOP approval that goes head-to-head with Regeneron — while Marea's own MAR002 acromegaly program remains the clearest bridge between the two segments following its merger with Lisata.
    7 min
  • Acromegaly Update — Monday September 21, 2026
    This week's acromegaly literature centers on long-term disease burden — cardiovascular morbidity, musculoskeletal disease, and precision-medicine treatment selection — while the rare disease industry notched a landmark ultra-rare gene therapy approval, a $1.65B radiopharma merger, and a $123M bet on an oral thyroid eye disease pill.
    7 min
  • Acromegaly Update — Tuesday September 15, 2026
    It's a quiet week for acromegaly-specific research — just one review paper worth flagging — but rare disease industry news was busy, headlined by Scholar Rock's first-ever muscle-targeted SMA approval and a rough week for two RNA-based rare disease programs at Novartis.
    7 min
  • Acromegaly Update — Monday September 7, 2026
    It's a thin week for acromegaly-specific research — no top-tier-journal hits, so we're covering the best next-tier evidence on GH-axis physiology, octreotide drug delivery, and pituitary imaging AI — while rare disease industry news delivers a sharp one-two: Ionis just won the first-ever approval for Alexander disease, days after Ultragenyx's marquee Angelman syndrome drug flopped in Phase 3.
    7 min
  • Acromegaly Update — Tuesday September 1, 2026
    It's a quiet week for dedicated acromegaly research — no top-tier-journal hits, just a pasireotide cost-effectiveness review and a giant-adenoma case report — while the wider rare disease industry absorbed a surprise Phase 3 failure in the ATTR-CM heart drug market and a fresh round of White House drug-pricing deals touching major rare-disease manufacturers.
    7 min

About Acromegaly Update

From the publisher's feed

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.